Thank you for your
interest in NK-92®cells
ImmunityBio is the originator, proprietor and custodian of NK-92, the widely known natural killer cell line, established in continuous culture in 1992.
ImmunityBio makes these cells available for patent identity purposes and for basic science research by not-for-profit entities through a limited-use license or material transfer agreement, provided that such limited-use excludes value creation of an exclusive nature that can be subsequently exploited commercially, directly or indirectly.
All such excluded uses, irrespective of the non-profit status of the requesting entity, shall require a commercial license, as described below.
NK-92 Cell Line
ImmunityBio has designated and exclusively authorized its affiliate, Brink Biologics, Inc., to make, license and distribute ImmunityBio’s proprietary NK-92 cells and its derivatives available to ‘for-profit’ entities for non-clinical applications.
For-profit entities require a license, irrespective of intended use. Access to our cells for such non-clinical applications as in vitro testing for product discovery, research and development, and bioanalytical testing as part of commercial manufacturing, are provided through Brink Biologic’s Neukopanel® Licensing Program.
Brink Biologics holds the exclusive rights to and is the only authorized distributor of NK-92, NK-92MI and all NK-92.CD16 variants for non-clinical use by for-profit entities worldwide. To begin the process, please click the button below.
Parties interested in clinical applications of our NK-92 cells and its derivatives may click the button below to inquire further.